Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationEBIATLeasesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Receivables - Net
Ratios

Soleno Therapeutics (SLNO) EBIAT (2016 - 2025)

Soleno Therapeutics (SLNO) has disclosed EBIAT for 9 consecutive years, with $43.4 million as the latest value for Q4 2025.

  • Quarterly EBIAT changed N/A to $43.4 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $20.9 million through Dec 2025, changed N/A year-over-year, with the annual reading at $20.9 million for FY2025, 111.89% up from the prior year.
  • EBIAT for Q4 2025 was $43.4 million at Soleno Therapeutics, up from $26.0 million in the prior quarter.
  • The five-year high for EBIAT was $43.4 million in Q4 2025, with the low at -$43.8 million in Q1 2025.